After the DEA Hearing: What the Stay Really Means for Rescheduling

October 11, 2026

Photo by Malcolm Hill via Pexels.

Eleven hearing days. Fourteen witnesses. A closed evidentiary record, sealed by post-hearing briefs filed August 17, 2026. By the end of summer, the marijuana rescheduling hearing before DEA's Chief Administrative Law Judge, Derek C. Julius, looked like it was heading toward a recommendation -- the kind of procedural finish line that's been years in the making since HHS first recommended moving marijuana to Schedule III back in 2023. Then, on September 29, 2026, Julius hit pause. A stay motion grounded in a newly published Government Accountability Office report froze the timeline just as it looked ready to move.

This isn't a technicality that only hearing-room regulars should care about. The GAO report at the center of the stay doesn't argue about marijuana's medical value one way or the other -- it asks whether DEA's scheduling process itself has documented, defensible rules for how staff make these calls at all. That's a bigger question than cannabis, and it's exactly the kind of systemic issue that tends to outlive any single case that raises it.

The near-term question is narrow and answerable, even if the stakes feel large: will Judge Julius reopen a record he already closed, and what does DEA's own adjudicative history say about how often that happens? Spoiler, grounded in precedent rather than guesswork -- not often, and not easily. Readers should also keep two separate tracks straight, because it's easy to conflate them: the stayed administrative hearing on Schedule I-to-III reclassification is one thing, and the separate D.C. Circuit challenge to DOJ's already-effective April 2026 order is another, still-moving thing entirely. They run on different clocks, with different judges, different legal theories, and -- so far -- different outcomes.

Eleven Days in Arlington: How We Got Here

Photo by Michael D Beckwith via Pexels.

The hearing itself ran June 29 through July 15, 2026, inside DEA headquarters in Arlington, Virginia -- eleven contested days before Chief ALJ Derek C. Julius, the kind of extended administrative proceeding that doesn't happen for routine scheduling actions. Fourteen witnesses testified in total, and the split tells you almost everything about how this fight is actually structured: only two witnesses testified in favor of rescheduling, while twelve witnesses, drawn from seven separate opposing entities, argued against it. That's not a close contest on paper. It's a lopsided record, built deliberately by organizations that understood early on that the strength of their written record would matter more later than how the hearing days themselves played in the room.

Post-hearing briefs closed out the evidentiary record on August 17, 2026, which is the procedural moment that matters most here. Once briefs are filed and the record closes, Julius's job becomes narrower: synthesize the testimony and exhibits into a recommended decision for DEA Administrator Terry Cole, who holds final authority over whatever happens next administratively. That's the ordinary path. The twelve-against-two witness imbalance wasn't just a courtroom dynamic -- it became the factual and argumentative foundation that opponents later cited when they asked Julius to stop the clock entirely, because a deep opposition record is exactly what you want in hand before you ask a judge to reconsider anything.

Worth being precise about what's actually being decided here: this hearing concerns the Schedule I-to-Schedule III reclassification question specifically -- the administrative rescheduling process DEA itself controls. It's a separate legal animal from the Department of Justice's own order, issued months earlier, which took its own independent action on marijuana's status for a narrower category of state-licensed medical use. Conflating the two tracks is the easiest mistake to make in this story, and it's one worth avoiding from the outset, because the next sections hinge on keeping them apart.

The GAO Report That Stopped the Clock

Photo by cottonbro studio via Pexels.

The stay motion came from three of the opponents who testified in July: DUID Victim Voices, Dr. Kenneth Finn, and the National Drug and Alcohol Association -- plaintiffs and witnesses who had already built a substantial opposition record during the hearing itself. Their vehicle for reopening the case was a GAO report, published September 23, 2026, reviewing how DEA has handled scheduling actions between 2020 and 2025.

What the report actually found is more nuanced than either side's framing suggests, and it's worth stating plainly rather than editorializing. GAO reviewed 84 DEA scheduling actions that required alignment with federal health recommendations over that five-year window, and found DEA's decisions matched those recommendations in all 84 cases. That's not a finding of agency failure on substance. The procedural flag is the part that mattered to Julius: GAO reported that DEA lacks documented internal policies spelling out staff roles and procedures for how scheduling decisions actually get made. In plain terms -- the outcomes tracked health guidance consistently, but the paper trail showing how DEA gets from recommendation to decision isn't formally written down anywhere GAO could verify.

That distinction is the entire ballgame for this stay. Opponents aren't arguing marijuana's pharmacology changed, or that new clinical evidence emerged, or that HHS got the science wrong. They're arguing DEA's scheduling machinery -- the institutional process itself, as it applies to every drug DEA schedules, not just cannabis -- hasn't been shown to run on documented rules. Julius apparently found that argument serious enough to warrant a pause: he issued the stay on September 29, 2026, delaying his recommended decision to Administrator Cole indefinitely while he considers whether the GAO report changes anything material.

It's a strange position for cannabis policy to be in, procedurally speaking. The case for rescheduling marijuana specifically isn't what's under direct attack right now. What's under attack is whether the agency empowered to decide that question -- and every other scheduling question before it -- can show its work. That's a GAO-sized problem, not a cannabis-sized one, and it's why this stay has implications well past the plant at the center of it.

Why Reopening a Closed Record Is Hard to Win

Photo by succo via Pixabay.

DEA administrative adjudications set a genuinely high bar for reopening a closed evidentiary record, and that bar exists for a reason: without it, every losing side in a hearing could indefinitely relitigate by filing one more motion after briefs close. The standard generally applied in agency proceedings like this one requires something close to extraordinary justification -- new evidence that is both genuinely unavailable at the time of the original hearing and material enough to plausibly change the outcome. It's not enough that a report restates concerns that witnesses already raised on the stand. It has to move the needle.

That's precisely the standard Julius now has to apply to the GAO report, and it cuts both ways. The historical pattern in federal agency adjudications is that records reopen for evidence nobody could have produced earlier -- a new study, a newly discovered document, a change in underlying facts -- not for secondary reports that synthesize or restate criticisms the parties already made during the hearing. Opponents of rescheduling were already arguing, during the eleven hearing days, that DEA's process was flawed. If the GAO report is read as simply confirming what witnesses already said in July, Julius has solid precedent to deny the stay and move forward.

But the counter-case is genuinely strong, and it deserves equal weight rather than a dismissive aside. GAO isn't a private advocacy witness repeating talking points -- it's Congress's own nonpartisan watchdog, and its finding wasn't anecdotal. It's a review spanning 84 separate scheduling actions across five years, concluding there's no documented internal procedure governing how DEA staff execute scheduling decisions generally. That's a scope and source of evidence categorically different from witness testimony about this one case. Arguably, that's exactly the kind of new, material, independently sourced evidence that reopening standards are designed to accommodate -- a congressional audit finding a systemic gap is a different animal than a party restating its position with more conviction.

The next real signal lands October 13, 2026: the government's deadline to respond to the stay motion, and the response is capped at twenty pages, double-spaced, one-inch margins. That's an unusually tight constraint for a matter with this much riding on it, and it tells you something about how DEA's own procedural rules box in even the agency's response to a challenge about its procedures. How DEA uses those twenty pages -- whether it leans on precedent to argue the GAO report changes nothing, or concedes ground on the documentation gap -- will be the first real tell on which way Julius is likely to lean.

The Other Track: D.C. Circuit Already Moving

Photo by 12019 via Pixabay.

While the administrative hearing sits frozen, a separate and already-consequential track keeps moving: the Department of Justice's own final order, AG Order No. 6752-2026, issued April 28, 2026. That order moved FDA-approved cannabis-derived drugs and state-licensed medical marijuana to Schedule III directly, through DOJ's own rulemaking authority rather than through the DEA hearing process described above. It's already in effect. The stayed hearing has no power to undo it, because it was never the vehicle that created it in the first place.

That order is now under direct legal attack in the D.C. Circuit, where three petitions have been consolidated into a single challenge: one from Smart Approaches to Marijuana together with the National Drug and Alcohol Association, one from the attorneys general of Indiana and Nebraska (Louisiana's AG withdrew from the challenge), and one from a coalition that includes MMJ International Holdings. Different petitioners, overlapping legal theory: that DOJ exceeded its statutory authority under 21 U.S.C. Section 811(d)(1) by issuing this order the way it did, leaning on the 1977 D.C. Circuit precedent in NORML v. DEA as the anchor case for what that authority does and doesn't permit.

The early signal from the court hasn't favored the challengers. On September 9, 2026, the D.C. Circuit declined to freeze DOJ's rule while the broader challenge to its legality proceeds -- meaning the medical marijuana reschedule under Order 6752-2026 stands and continues operating right now, even as its ultimate legal validity gets argued out over the coming months. Declining to grant a freeze isn't the same as ruling on the merits, but it's a meaningful signal: courts generally only issue that kind of freeze when they think the challenger is likely to win and irreparable harm is otherwise probable. Neither element apparently persuaded the panel here.

The practical takeaway for anyone trying to track this is simple but easy to get wrong: a stayed administrative hearing and an already-effective, separately litigated DOJ rule can coexist without contradiction. They're not the same clock, they're not resolved by the same decision-maker, and a setback or delay in one doesn't automatically touch the other. Right now, one track is frozen and one is live.

Reading the Timeline: What Near-Term Precedent Suggests

Photo by webandi via Pixabay.

Reasoning from DEA's own recent track record is more useful here than speculating about what anyone wants to happen. Of the 84 scheduling actions GAO reviewed from 2020 through 2025, movement once a health recommendation was finalized tended to happen on the order of months, not years -- the bottleneck in those cases was rarely scientific disagreement, since outcomes matched HHS and FDA guidance in all 84 instances. That pattern suggests the current slowdown is a process problem layered onto this one case, not evidence that the underlying scientific question is suddenly less settled than it was in 2023.

Two paths split from here, and the stakes of each are genuinely different. If Julius denies the stay motion -- the historically likely outcome, given how high the extraordinary-justification bar sits for reopening a closed record -- his recommendation to Administrator Cole could still arrive within the near-term window this piece is framed around, plausibly landing late 2026 into 2027. If he grants it instead, the record reopens for new evidence and additional briefing, and that realistically pushes any recommendation into mid-to-late 2027. That's not a guess pulled from nowhere -- it tracks how past contested DEA reschedulings behaved once procedural challenges were let in the door, the hydrocodone combination product rescheduling being a comparable case where admitting procedural objections stretched what otherwise would have been a faster process.

There's a second lever sitting alongside Julius's decision that could matter just as much regardless of what he rules: the D.C. Circuit's eventual merits decision on the Section 811(d)(1) authority question. If that court ultimately sides with the petitioners -- Smart Approaches to Marijuana, the Indiana and Nebraska AGs, and the MMJ International Holdings coalition -- on the theory that DOJ overstepped its statutory authority, it could unsettle the legal footing of the administrative rescheduling process too, independent of anything Julius decides about this specific stay. The two tracks are procedurally separate, but a sufficiently broad ruling on agency authority wouldn't necessarily respect that separation.

Grain of salt, because both forecasts above depend on variables outside the legal reasoning itself: Administrator Cole's own posture once a recommendation reaches his desk, which D.C. Circuit panel eventually hears the merits and how it reads NORML v. DEA, and whether Congress acts first. An appropriations rider or a standalone THC-specific bill has mooted parts of cannabis policy fights before, and there's no structural reason that couldn't happen again here, potentially making part of this entire sequence irrelevant before either judge reaches a final answer.

What This Means for the Industry in the Meantime

Photo by Tima Miroshnichenko via Pexels.

For operators and investors trying to plan around this, the practical reality is less dramatic than the headlines suggest, at least for now. Plenty of state-licensed medical cannabis businesses built updated financial models around the 280E tax relief that comes with Schedule III status -- the provision that currently bars cannabis businesses from deducting ordinary business expenses because they're trafficking in a Schedule I substance. The September 29 stay freezes the separate administrative hearing, but it does not reverse DOJ's April order. That means the 280E relief tied to Order 6752-2026 currently still stands for the state-licensed medical operators it covers, because that order's validity is being tested in the D.C. Circuit, not undone by anything happening in Arlington.

That said, uncertainty itself functions as a real cost, independent of which way any individual ruling eventually goes. Investors and multi-state operators have a documented history of pricing in rescheduling delays as discounted near-term valuations -- the pattern showed up clearly after both the 2016 and 2020 federal denials of earlier rescheduling petitions, when expected near-term movement didn't materialize and capital responded by pulling in its time horizon. There's no reason to expect this cycle behaves differently; a frozen hearing plus an ongoing appellate challenge is exactly the kind of prolonged ambiguity that tends to get discounted rather than ignored.

There's a genuine business opportunity opening up in the margins of this uncertainty, and it's worth naming directly. Compliance and legal-consulting firms that specialize in navigating parallel-track federal cannabis litigation -- advising clients on how to structure operations and tax positions when one legal track is live and another is frozen -- are seeing real, current demand for a niche that barely existed as a distinct specialty before 2024. That's a direct byproduct of exactly this kind of split-track legal landscape, and it's likely to keep growing for as long as the administrative and judicial tracks keep moving independently of each other.

The next concrete data point worth watching isn't a final ruling -- it's October 13, 2026, the government's deadline to respond to the stay motion within that tight twenty-page limit. It won't resolve anything on its own. But it's the first moment DEA itself has to characterize, on the record, how seriously it takes GAO's procedural critique -- and that framing will shape how Julius, and eventually Cole, approach everything that follows.

Strip away the procedural detail and the stay boils down to one fact worth holding onto: nobody paused this process because the medical evidence on marijuana changed, or because HHS reversed its position, or because the 84 scheduling actions GAO reviewed turned up a bad call. The stay exists because a congressional watchdog found DEA can't fully document how its own scheduling machinery operates -- and that question is bigger than, and will outlast, this one case about this one plant.

Expect the two tracks to keep running on different clocks for at least another year. DOJ's April order already moved FDA-approved drugs and state-licensed medical marijuana to Schedule III, it's already in effect, and the D.C. Circuit's September 9 decision not to freeze it while the authority challenge proceeds means that practical relief keeps standing for now. The formal administrative rescheduling, by contrast, sits frozen behind a stay motion that has to clear a historically difficult bar before Julius's recommendation ever reaches Administrator Cole's desk. Both outcomes are plausible on reasonable timelines; neither is guaranteed, and Congress retains the ability to render parts of this moot before either judge finishes.

The more durable takeaway may have nothing to do with cannabis specifically. If GAO's finding about undocumented scheduling procedures sticks and forces DEA to formalize how it handles future scheduling decisions, that precedent will matter far more the next time a contested Schedule I substance comes up for review than it ultimately matters for marijuana, which already has an independent, live path to relief running through DOJ's order. Cannabis, in other words, may end up being the test case that fixes a plumbing problem for every drug reclassification that comes after it -- which is a stranger and more consequential legacy than simply being the substance that did or didn't get rescheduled this year.